Immunotherapy combo aims to boost survival in tough head & neck cancer
NCT ID NCT05340270
Summary
This study is testing whether adding an immunotherapy drug (a PD-1 inhibitor) to standard chemotherapy before a patient's main cancer treatment can help people with advanced nasopharyngeal cancer live longer without their cancer returning. It involves 150 participants who are randomly assigned to receive either the new combination or standard care. The goal is to see if this approach improves survival rates and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.